About ADVITOS
ADVITOS is a company based in Munchen (Germany) founded in 2005. ADVITOS has raised $23.79 million across 4 funding rounds from investors including EIT Health, European Union and Crédit Mutuel Equity. The company has 88 employees as of December 31, 2020. ADVITOS offers products and services including ADVOS BK300. ADVITOS operates in a competitive market with competitors including TransMedics, OrganOx, Paragonix Technologies, Bridge to Life and Vascular Perfusion, among others.
- Headquarter Munchen, Germany
- Employees 88 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Advitos Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$23.79 M (USD)
in 4 rounds
-
Latest Funding Round
$23.79 M (USD), Series B
Jun 22, 2021
-
Investors
EIT Health
& 2 more
-
Employee Count
88
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ADVITOS
ADVITOS offers a comprehensive portfolio of products and services, including ADVOS BK300.
Provides integrated therapies for organ support in intensive care settings.
People of ADVITOS
Unlock access to complete
Funding Insights of ADVITOS
ADVITOS has successfully raised a total of $23.79M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $23.79 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ADVITOS
ADVITOS has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include EIT Health, European Union and Crédit Mutuel Equity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Growth and acquisition investments are managed by Credit Mutuel Equity.
|
Locked | Locked | Locked | |
|
Healthcare startups are accelerated and incubated through specialized programs.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for ADVITOS
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ADVITOS
Investment portfolio details for ADVITOS
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ADVITOS
Detailed financials for ADVITOS
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Advitos Comparisons
Peer comparison for ADVITOS
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ADVITOS
ADVITOS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TransMedics, OrganOx, Paragonix Technologies, Bridge to Life and Vascular Perfusion, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of organ transplantation technology
|
|
| Locked | Locked | Locked |
Warm storage and transport systems for harvested organs are provided.
|
|
| Locked | Locked | Locked |
Organ preservation and transport systems are developed for transplants.
|
|
| Locked | Locked | Locked |
Cold storage solutions for organ transplant preservation are provided.
|
|
| Locked | Locked | Locked |
Developer of a device for organ preservation
|
Detailed competitors of ADVITOS
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Advitos
Complete news archive for ADVITOS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ADVITOS
ADVITOS was founded in 2005 and raised its 1st funding round 14 years after it was founded.
ADVITOS is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
Claus Jessen is the current CEO of ADVITOS.
ADVITOS is a funded company, having raised a total of $23.79M across 4 funding rounds to date.
As of Dec 31, 2020, the latest employee count at ADVITOS is 88.
Founded in 2005 in Munich, Germany, multi-organ support systems are developed and provided by ADVITOS for liver, lung, kidney functions, and acid-base balance. These systems represent an advancement over traditional dialysis. The ADVOS device is utilized for extracorporeal removal of carbon dioxide, hepatic toxins, water-soluble and protein-bound nephrotoxins, alongside correction of metabolic and respiratory acidosis. Operations focus on medical device innovation in the healthcare sector.
ADVITOS's top competitors include TransMedics, OrganOx and Paragonix Technologies.
ADVITOS offers ADVOS BK300.
ADVITOS has 3 investors. Key investors include EIT Health, European Union, and Crédit Mutuel Equity.